Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

PURPOSE: Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC. PATIENTS AND METHODS: El...

Descripción completa

Detalles Bibliográficos
Autores principales: Lluch, Ana, Barrios, Carlos H., Torrecillas, Laura, Ruiz-Borrego, Manuel, Bines, Jose, Segalla, Jose, Guerrero-Zotano, Ángel, García-Sáenz, Jose A., Torres, Roberto, de la Haba, Juan, García-Martínez, Elena, Gómez, Henry L., Llombart, Antonio, Bofill, Javier Salvador, Baena-Cañada, José M., Barnadas, Agustí, Calvo, Lourdes, Pérez-Michel, Laura, Ramos, Manuel, Fernández, Isaura, Rodríguez-Lescure, Álvaro, Cárdenas, Jesús, Vinholes, Jeferson, Martínez de Dueñas, Eduardo, Godes, Maria J., Seguí, Miguel A., Antón, Antonio, López-Álvarez, Pilar, Moncayo, Jorge, Amorim, Gilberto, Villar, Esther, Reyes, Salvador, Sampaio, Carlos, Cardemil, Bernardita, Escudero, Maria J., Bezares, Susana, Carrasco, Eva, Martín, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968797/
https://www.ncbi.nlm.nih.gov/pubmed/31804894
http://dx.doi.org/10.1200/JCO.19.00904

Ejemplares similares

Ejemplares similares